Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1987 1
1988 3
1989 7
1990 8
1991 5
1992 6
1993 13
1994 15
1995 15
1996 33
1997 34
1998 29
1999 36
2000 31
2001 47
2002 56
2003 69
2004 70
2005 90
2006 95
2007 98
2008 84
2009 78
2010 91
2011 80
2012 122
2013 99
2014 95
2015 97
2016 109
2017 106
2018 84
2019 104
2020 106
2021 111
2022 101
2023 9
Text availability
Article attribute
Article type
Publication date

Search Results

1,997 results
Results by year
Filters applied: . Clear all
Page 1
Bicalutamide and the new perspectives for female pattern hair loss treatment: What dermatologists should know.
Carvalho RM, Santos LDN, Ramos PM, Machado CJ, Acioly P, Frattini SC, Barcaui CB, Donda ALV, Melo DF. Carvalho RM, et al. J Cosmet Dermatol. 2022 Oct;21(10):4171-4175. doi: 10.1111/jocd.14773. Epub 2022 Feb 10. J Cosmet Dermatol. 2022. PMID: 35032336 Review.
This review aimed to summarize and discuss the key information on this new therapy for FPHL. Bicalutamide has no diuretic effect. It does not cross the blood-brain barrier, and it has little effect on serum luteinizing hormone. Additionally, bicalutamide was found t …
This review aimed to summarize and discuss the key information on this new therapy for FPHL. Bicalutamide has no diuretic effect. It …
Radiation with or without Antiandrogen Therapy in Recurrent Prostate Cancer.
Shipley WU, Seiferheld W, Lukka HR, Major PP, Heney NM, Grignon DJ, Sartor O, Patel MP, Bahary JP, Zietman AL, Pisansky TM, Zeitzer KL, Lawton CA, Feng FY, Lovett RD, Balogh AG, Souhami L, Rosenthal SA, Kerlin KJ, Dignam JJ, Pugh SL, Sandler HM; NRG Oncology RTOG. Shipley WU, et al. N Engl J Med. 2017 Feb 2;376(5):417-428. doi: 10.1056/NEJMoa1607529. N Engl J Med. 2017. PMID: 28146658 Free PMC article. Clinical Trial.
The cumulative incidence of metastatic prostate cancer at 12 years was 14.5% in the bicalutamide group, as compared with 23.0% in the placebo group (P=0.005). ...Gynecomastia was recorded in 69.7% of the patients in the bicalutamide group, as compared with 10.9% of …
The cumulative incidence of metastatic prostate cancer at 12 years was 14.5% in the bicalutamide group, as compared with 23.0% in the …
Clinical Efficacy of Enzalutamide vs Bicalutamide Combined With Androgen Deprivation Therapy in Men With Metastatic Hormone-Sensitive Prostate Cancer: A Randomized Clinical Trial.
Vaishampayan UN, Heilbrun LK, Monk P 3rd, Tejwani S, Sonpavde G, Hwang C, Smith D, Jasti P, Dobson K, Dickow B, Heath EI, Semaan L, Cher ML, Fontana JA, Chinni S. Vaishampayan UN, et al. JAMA Netw Open. 2021 Jan 4;4(1):e2034633. doi: 10.1001/jamanetworkopen.2020.34633. JAMA Netw Open. 2021. PMID: 33496795 Free PMC article. Clinical Trial.
OBJECTIVE: To compare the efficacy of enzalutamide vs bicalutamide in combination with ADT in men with mHSPC, with a subset analysis of Black patients. ...The 12-month PSA response rates were 84% with enzalutamide and 34% with bicalutamide. CONCLUSIONS AND RELEVANCE …
OBJECTIVE: To compare the efficacy of enzalutamide vs bicalutamide in combination with ADT in men with mHSPC, with a subset analysis …
Enzalutamide Versus Bicalutamide in Castration-Resistant Prostate Cancer: The STRIVE Trial.
Penson DF, Armstrong AJ, Concepcion R, Agarwal N, Olsson C, Karsh L, Dunshee C, Wang F, Wu K, Krivoshik A, Phung D, Higano CS. Penson DF, et al. J Clin Oncol. 2016 Jun 20;34(18):2098-106. doi: 10.1200/JCO.2015.64.9285. Epub 2016 Jan 25. J Clin Oncol. 2016. PMID: 26811535 Clinical Trial.

RESULTS: Enzalutamide reduced the risk of progression or death by 76% compared with bicalutamide (hazard ratio [HR], 0.24; 95% CI, 0.18 to 0.32; P < .001). ...CONCLUSION: Enzalutamide significantly reduced risk of prostate cancer progression or death compared with bi

RESULTS: Enzalutamide reduced the risk of progression or death by 76% compared with bicalutamide (hazard ratio [HR], 0.24; 95% CI, 0. …
Abiraterone acetate versus nonsteroidal antiandrogen with androgen deprivation therapy for high-risk metastatic hormone-sensitive prostate cancer.
Yanagisawa T, Kimura T, Mori K, Suzuki H, Sano T, Otsuka T, Iwamoto Y, Fukuokaya W, Miyajima K, Enei Y, Sakanaka K, Matsukawa A, Onuma H, Obayashi K, Tsuzuki S, Hata K, Shimomura T, Miki J, Egawa S. Yanagisawa T, et al. Prostate. 2022 Jan;82(1):3-12. doi: 10.1002/pros.24243. Epub 2021 Sep 24. Prostate. 2022. PMID: 34559410
Bicalutamide was given at 80 mg daily and abiraterone was given at 1000 mg daily as four 250-mg tablets plus prednisolone (5-10 mg daily). ...Impaired liver function was noted in 2% of the bicalutamide group and 16% of the abiraterone group (p < 0.001). Median fo
Bicalutamide was given at 80 mg daily and abiraterone was given at 1000 mg daily as four 250-mg tablets plus prednisolone (5-10 mg da
Iron Induces Cell Death and Strengthens the Efficacy of Antiandrogen Therapy in Prostate Cancer Models.
Bordini J, Morisi F, Elia AR, Santambrogio P, Pagani A, Cucchiara V, Ghia P, Bellone M, Briganti A, Camaschella C, Campanella A. Bordini J, et al. Clin Cancer Res. 2020 Dec 1;26(23):6387-6398. doi: 10.1158/1078-0432.CCR-20-3182. Epub 2020 Sep 14. Clin Cancer Res. 2020. PMID: 32928793
EXPERIMENTAL DESIGN: We analyzed markers of cell viability and mechanisms underlying iron toxicity in androgen receptor-positive VCaP and LNCaP, castration-resistant DU-145 and PC-3, and murine TRAMP-C2 cells treated with iron and/or the antiandrogen bicalutamide. We valid …
EXPERIMENTAL DESIGN: We analyzed markers of cell viability and mechanisms underlying iron toxicity in androgen receptor-positive VCaP and LN …
Efficacy and safety of enzalutamide versus bicalutamide for patients with metastatic prostate cancer (TERRAIN): a randomised, double-blind, phase 2 study.
Shore ND, Chowdhury S, Villers A, Klotz L, Siemens DR, Phung D, van Os S, Hasabou N, Wang F, Bhattacharya S, Heidenreich A. Shore ND, et al. Lancet Oncol. 2016 Feb;17(2):153-163. doi: 10.1016/S1470-2045(15)00518-5. Epub 2016 Jan 14. Lancet Oncol. 2016. PMID: 26774508 Clinical Trial.
The objective of the TERRAIN study was to compare the efficacy and safety of enzalutamide with bicalutamide in patients with metastatic castration-resistant prostate cancer. ...Of the most common adverse events, those occurring more frequently with enzalutamide than with …
The objective of the TERRAIN study was to compare the efficacy and safety of enzalutamide with bicalutamide in patients with metastat …
Rezvilutamide versus bicalutamide in combination with androgen-deprivation therapy in patients with high-volume, metastatic, hormone-sensitive prostate cancer (CHART): a randomised, open-label, phase 3 trial.
Gu W, Han W, Luo H, Zhou F, He D, Ma L, Guo H, Liang C, Chong T, Jiang J, Chen Z, Wang Y, Zou Q, Tian Y, Xiao J, Huang J, Zhu S, Dong Q, Zhang X, Li H, Yang X, Chen C, Li J, Jin C, Zhang X, Ye D; CHART Investigators. Gu W, et al. Lancet Oncol. 2022 Oct;23(10):1249-1260. doi: 10.1016/S1470-2045(22)00507-1. Epub 2022 Sep 5. Lancet Oncol. 2022. PMID: 36075260 Clinical Trial.
In this study, we aimed to evaluate the efficacy and safety of rezvilutamide versus bicalutamide in combination with androgen-deprivation therapy (ADT) for high-volume, metastatic, hormone-sensitive prostate cancer. ...Serious adverse events were reported in 90 (28%) of 32 …
In this study, we aimed to evaluate the efficacy and safety of rezvilutamide versus bicalutamide in combination with androgen-depriva …
Treatment of bicalutamide-induced breast events.
Sieber PR. Sieber PR. Expert Rev Anticancer Ther. 2007 Dec;7(12):1773-9. doi: 10.1586/14737140.7.12.1773. Expert Rev Anticancer Ther. 2007. PMID: 18062751 Review.
Bicalutamide is a competitive nonsteroidal androgen receptor antagonist. ...The ongoing bicalutamide Early Prostate Cancer (EPC) program has shown that breast events, defined as gynecomastia, breast pain or both, are a significant limitation of bicalutamide.
Bicalutamide is a competitive nonsteroidal androgen receptor antagonist. ...The ongoing bicalutamide Early Prostate Cancer (EP
1,997 results